Abstract 1434P
Background
FRUTIGA study showed OS improvement but was not statistically significant in the ITT population who had advanced G/GEJ adenocarcinoma receiving F plus PTX over placebo plus PTX (mOS: 9.67 vs 8.41 mo, HR=0.96, p=0.6064; Xu RH, et al, 2024 ASCO #438780). Here we explored the effect of subsequent anti-tumor therapies on OS in this study.
Methods
A post-hoc analysis for the effect of subsequent anti-tumor therapies on OS (randomization to death from any cause) using Kaplan-Meier method was conducted.
Results
A total of 439/703 pts (F+PTX vs placebo + PTX: 185/351 [52.7%] vs 254/352 [72.2%]) received subsequent anti-tumor therapies. There were 33.7% (28.2% vs 39.2%), 16.9% (14.2% vs 19.6%), and 9.1% (7.4% vs 10.8%) of pts received 1, 2 or ≥ 3 subsequent anti-tumor regimens, respectively. Apatinib (23.1% vs 35.2%), irinotecan (20.8% vs 27.8%) and anti PD-1/PD-L1 antibodies (20.8% vs 27.6%) were the most common subsequent regimens; few pts (3.4% vs 5.7%) used anti-HER2/Claudin 18.2 regimens. Detailed results of impact of subsequent anti-tumor therapies on OS are shown in the table below. Table: 1434P
| F+PTX (N = 351) n (%) | PTX (N = 352) n (%) | Median OS, mo (F+PTX vs PTX) | HR | |
| Subsequent treatment | 185 (52.7) | 254 (72.2) | 12.22 vs 9.95 | 0.91 (0.73, 1.12) |
| Apatinib | 81 (23.1) | 124 (35.2) | 13.01 vs 10.81 | 0.95 (0.70, 1.30) |
| Irinotecan | 73 (20.8) | 98 (27.8) | 12.22 vs 10.71 | 0.92 (0.67, 1.27) |
| Anti PD-1/PD-L1 – ICI naïve# | 68 (19.4) | 86 (24.4) | 13.90 vs 13.60 | 1.12 (0.77, 1.62) |
| Anti PD-1/PD-L1 – ICI pre-treated∗ | 5 (1.4) | 11 (3.1) | 14.52 vs 14.75 | 0.73 (0.18, 2.94) |
| Anti HER2/Claudin 18.2& | 12 (3.4) | 20 (5.7) | 13.77 vs 16.10 | 2.09 (0.82, 5.30) |
∗Pts who had received prior anti PD-1/PD-L1 antibodies treatment.#Pts who had not received prior anti PD-1/PD-L1 antibodies treatment.&Pts who had not received prior HER2.
Conclusions
Pts who received 3L standard regimens (apatinib, irinotecan) for the subsequent anti-tumor therapies had the consistent OS improvement as shown in ITT population. Subsequent anti PD-1/PD-L1 therapies for pts who had received previous anti PD-1/PD-L1 antibodies could have no potential impact on OS benefit in FRUTIGA study.
Clinical trial identification
NCT03223376.
Editorial acknowledgement
Legal entity responsible for the study
Hutchmed Limited.
Funding
The National Science and Technology Major Project (project no. 2019ZX09301012), the Science and Technology Commission of Shanghai Municipality (Science, Technology and Innovation Action Plan, project no. 17431900100) and Hutchmed Limited.
Disclosure
P. Tan, W. Su: Financial Interests, Personal, Full or part-time Employment: Hutchmed Limited. All other authors have declared no conflicts of interest.
Resources from the same session
567P - Interim endoscopic restaging after induction chemotherapy to predict complete response and survival after total neoadjuvant therapy in low rectal cancer: Ad-hoc analysis of the IMPACT trial
Presenter: Eiji Shinozaki
Session: Poster session 16
568P - Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort
Presenter: Sepehr Doroudian
Session: Poster session 16
569P - Mismatch repair deficient, stage II/III rectal cancer: Real-world patient, tumour, and treatment characteristics in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
571P - Neoadjuvant chemotherapy with FOLFIRINOX and short course radiotherapy in locally advanced rectal caner (ISANOX): A prospective phase II trial
Presenter: Feryel Letaief-Ksontini
Session: Poster session 16
572P - Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial
Presenter: Thomas Aparicio
Session: Poster session 16
573P - M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial
Presenter: Valentina Boni
Session: Poster session 16
574P - First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study
Presenter: Zhen Yu Lin
Session: Poster session 16
575P - Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results
Presenter: Andrew Hendifar
Session: Poster session 16
576P - Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study
Presenter: Jifang Gong
Session: Poster session 16